Skip to main content

Roche Gets FDA OK for Mycoplasma Detection Kit

NEW YORK (GenomeWeb News) – Roche said today that the US Food and Drug Administration has accepted the use of Roche's PCR-based mycoplasma detection test for release testing of a Roche biopharmaceutical product.

Roche said that its test, called MycoTool, is the first commercially available mycoplasma PCR test accepted by the FDA for release testing of a biopharmaceutical product.

Mycoplasms frequently cause contamination in biopharmaceutical production, cell therapy, tissue engineering, and vaccine manufacturing. Traditional detection methods, required by pharmacopoeias and drug regulating agencies worldwide, use growth on culture media and in vitro assays to detect contaminating organisms.

Such tests, Roche said, require as many as 28 days to complete and are laborious and difficult to interpret. MycoTool, on the other hand, takes approximately one day to complete.

In April 2011, Swiss pharmaceutical products and services firm Lonza became the distributor of MycoTool under a co-exclusive agreement between the companies.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.